NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Roivant Sciences Ltd. (ROIV) Stock Analysis

Roivant Sciences Ltd. (ROIV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ROIV

$34.93

+$0.52 (+1.51%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ROIV with… →

ROIV Key Statistics

As of Sep 4, 2026
Trading
Open
$34.20
Previous Close
$34.41
Day's Range
33.88–35.15
52-Week Range
12.55–37.97
Volume
5.24M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.12
Valuation
Market Cap
$25.23B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3349.81
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.48
Financials (FY)
Revenue (FY)
$8.26M−71.57%
Net Income (FY)
−$299.77M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
722.32M
1-Year Return
+177.88%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
6.27M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ROIV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+60.97%
2025+83.43%
2024+5.34%
2023+40.55%
2022−20.73%
2021−0.88%
2020 (partial year)−2.21%

As of September 4, 2026.

ROIV Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$8.26M−$299.77M−3629.2%
2024$29.05M−$171.98M−592.0%
2023$32.71M$4.35B13294.2%
2022$31.53M−$1.01B−3200.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.26M$6.98M−$1.29B−$299.77M−3629.2%
2024$29.05M$28.14M−$1.11B−$171.98M−592.0%
2023$32.71M$31.11M−$824.93M$4.35B13294.2%
2022$31.53M$28.50M−$809.01M−$1.01B−3200.2%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

ROIV Valuation vs Biotechnology Median

Median of 656 stocks
MetricROIVBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Roivant Sciences Ltd. (ROIV) carries a market capitalisation of $25.23B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 721 employees.

Over the past 52 weeks the price has ranged from $12.55 to $37.97. ROIV last closed at $34.93 on September 4, 2026. That is +$0.52 (+1.51%) against the previous close. The latest close sits 178.44% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $8.26M. That is −71.57% against the prior fiscal year, when revenue was $29.05M. The same year closed with a net loss of $299.77M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.48.

Across the 4 fiscal years on file, revenue moves from $31.53M in 2022 to $8.26M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3,349.81 times revenue. On price-to-sales that is 219.5 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +177.88%. Across 5 years the annualized return works out at +28.53%. Beta against the wider market is reported at 1.12. Annualized volatility over the trailing 5 years is 59.3%.

Growth & Income

No dividend is on file for ROIV.

Across the complete calendar years on file, 2025 returned +83.43% and 2022 returned −20.73%. Of the 5 complete calendar years on file, 3 finished higher. 2026 is still running; the price is +60.97% year to date.

Peer Comparison

Roivant Sciences Ltd. (ROIV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Roivant Sciences Ltd. ROIV $25.23B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Roivant Sciences Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Visit website →